特里普托利德通过抑制黑色素瘤中核酸切除修复 (NER) 活性来增强碳酸诱导的亡
Geng Wang1, Hongmin Guo2, Yan Ren1
1Health Science Center, Ningbo University, Ningbo, China.
Frontiers in pharmacology
|June 16, 2023
概括
三酸 (TPL) 结合碳酸 (CBP) 通过抑制DNA修复途径来增强黑色素瘤治疗. 这种协同效应改善了癌细胞的死亡,并减少了瘤的进展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 碳白 (CBP) 是一种破坏DNA的化疗剂,用于晚期黑色素瘤.
- 耐药性导致黑色素瘤患者的反应率低,存活时间短.
- 三胺 (TPL) 具有抗瘤特性,可以增强化疗药物的疗效.
研究的目的:
- 调查TPL和CBP对黑色素瘤的联合作用.
- 阐明TPL和CBP的协同作用背后的分子机制.
主要方法:
- 使用了黑色素瘤细胞系和异种移植小鼠模型.
- 评估了细胞活力,迁移,入侵,细胞亡和DNA损伤.
- 量化核酸切割修复 (NER) 途径蛋白质和测试的NER修复能力.
主要成果:
- 当与CBP结合时,TPL可以选择性地抑制NER通路活性.
- TPL与CBP表现出协同作用,减少细胞活力,迁移和入侵,同时促进黑色素瘤细胞的亡.
- 结合TPL和CBP治疗在体内显著抑制瘤生长,通过抑制增殖和诱导亡.
结论:
- 托利德 (TPL) 作为核酸切割修复 (NER) 抑制剂.
- TPL显示出治疗黑色素瘤的巨大潜力,无论是作为独立疗法,还是与碳烯 (CBP) 结合使用.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
相关概念视频
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
